Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy

Rong-yun Mai1,2, Tao Bai1, Xiao-ling Luo2* and Guo-bin Wu1*

Abstract

Background: Systemic inflammatory response (SIR) plays a crucial role in every step of tumorigenesis and development. More recently, the fibrinogen-to-albumin ratio (FAR), an inflammation-based model, was suggested as a prognostic maker for various cancer patients. This research aimed to estimate the prognostic abilities of FAR, neutrophil–lymphocyte ratio (NLR), monocyte–lymphocyte ratio (MLR), platelet–lymphocyte ratio (PLR), and systemic immune–inflammation index (SII) in patients with hepatocellular carcinoma (HCC) subjected to curative hepatectomy.

Methods: A total of 1,502 cases who underwent hepatectomy for HCC were included. The predictive performances of FAR, NLR, MLR, PLR, and SII were assessed with regards to overall survival (OS) and disease-free survival (DFS). The area under the time-dependent receiver operating characteristic curve was used to compare prognostic performances.

Results: Data revealed that FAR had higher predictive accuracy than other inflammation-based models and alphafetoprotein (AFP) in assessing OS and DFS. Indeed, the OS and DFS of patients with high FAR (> 8.9), differentiated by the optimal cut-off value of FAR, were remarkably reduced (p < 0.05 for OS and DFS). Multivariate Cox regression analyses identified that AFP, FAR, clinically significant portal hypertension, tumor size, Barcelona Clinical Liver Cancer staging system, major resection and blood loss were independent indicators for predicting OS and DFS. Furthermore, these patients could be classified according to their FAR into significantly different subgroups, regardless of AFP levels (p < 0.05 for DFS and OS). Similar results were obtained in other inflammation-based prognostic models.

Conclusions: Compared with NLR, MLR, PLR, SII and AFP, FAR showed significant advantages in predicting survival of HCC patients subjected to liver resection.

Keywords: Hepatocellular carcinoma, Fibrinogen-to-albumin ratio, Prognosis, Systemic inflammation response

Background

Hepatocellular carcinoma (HCC) is the sixth most common type of cancers and the fourth major leading cause of cancer-associated death worldwide [1]. Partial liver resection is the major strategy for the radical treatment of HCC [2, 3]. However, even after complete resection, the long-term patient survival rate remained unsatisfactory due to high recurrence rates [4, 5]. Therefore, an accurate
and reliable model is needed to identify high-risk patients with poor prognoses and optimize their adjuvant therapy to achieve greater benefits.

Recently, systemic inflammation response (SIR) was shown to be an important distinguishing feature of malignant tumors since it is involved in every stage of tumorigenesis and development [4–6]. Many prognostic models based on the SIR have been established and are related to the prognosis of patients with different cancers. These models usually consist of leukocytes and acute-phase proteins from the circulatory system. Currently, several leukocyte-based inflammation models, such as the neutrophil-to-lymphocyte ratio (NLR) [7–9], monocyte-to-lymphocyte ratio (MLR) [10, 11], platelet-to-lymphocyte ratio (PLR) [12, 13], and systemic immune–inflammation index (SII) [14, 15], have been proved to be meaningful indicators for estimating adverse results in various cancers. Nevertheless, these leukocytes are often affected by other factors and therefore they may not reflect the inflammatory state of patients [4]. For example, patients that receive transcatheter arterial chemoembolization, radiofrequency ablation, or immunotherapy, have significantly reduced levels of circulating platelets, lymphocytes, neutrophils and monocytes [6]. Therefore, these leukocyte-based models maybe have limitations in assessing the poor outcomes of patients undergoing hepatectomy for HCC.

Apart from inflammation, the nutritional status is also related to the outcomes of cancer patients [16, 17]. The modified Glasgow outcome scale (mGPS) [18, 19] and C-reactive protein-to-albumin ratio (CAR) [20], are based on the two important acute phase proteins in SIR, namely C-reactive protein (CRP) and albumin [4], and are related to the prognosis of cancer patients. Nevertheless, in many treatment centers, CRP is not included as a routine measurement of patient care, which limits its clinical application [21]. In parallel, fibrinogen, a glycoprotein synthesized by liver cells, is the most abundant coagulation parameter in humans and is routinely measured [22]. Interestingly, plasma fibrinogen is also an acute phase protein in SIR, similar to CRP, which increases rapidly during inflammation [22]. After being converted to fibrin, it is actively involved in the coagulation process. Many researchers have confirmed that increased levels of plasma fibrinogen may predict adverse events for various cancers [21–25]. In addition, fibrinogen has been shown to have the same predictive power as CRP in assessing adverse outcomes in cancer patients [22]. Therefore, the fibrinogen-to-albumin ratio (FAR) [26–32], which is composed of plasma fibrinogen and serum albumin, combines the patient’s inflammation, coagulation and nutritional situation, and may be a valuable model to assess the poor outcomes of HCC patients.

Therefore, the purpose of this research was to estimate the capacity of FAR in the prognosis prediction of patients with HCC subjected to hepatectomy. Moreover, FAR was compared with other models, including NLR, MLR, PLR and SII.

Patients and methods

Patients

This study included all HCC patients who were subjected to hepatic resection with curative intent at Guangxi Medical University Cancer Hospital between December 2013 and December 2018. Patients who received other therapies for HCC before hepatectomy were excluded. The study was conducted in compliance with the Helsinki Declaration and approved by the institutional Ethics Committee of Guangxi Medical University Cancer Hospital, and all patients provided written informed consent.

Diagnosis and definitions

Cirrhosis and HCC were diagnosed on the basis of postoperative histological evidence. HCC staging was performed based on the Barcelona Clinical Liver Cancer (BCLC) staging System [33]. Clinically significant portal hypertension (CSPH) was defined as splenomegaly or gastroesophageal varices with thrombocytopenia [34]. Major hepatectomy was defined as the resection of 3 or more segments of the liver [35].

Calculation of systemic inflammation-based prognostic models

The prognostic models were calculated as: FAR = fibrinogen (mg/dL)/albumin (mg/dL) × 100; MLR = monocyte count/lymphocyte counts; NLR = neutrophil counts/lymphocyte counts; PLR = platelet counts/lymphocyte counts; SII = platelet counts × neutrophil counts/lymphocyte counts. Measurements were performed one week before hepatectomy. All indicators of the above formula were collected and analyzed within 1 week prior to hepatectomy.

Surgical procedure and follow-up

All patients included in this project were performed open hepatectomy when preoperative imaging showed that tumors could be removed with a good liver function reserve. Further details and indications of surgery were described in previous research [36].

After discharge, follow-up was performed 1 month after liver resection and every 3 months until withdrawal or death. At each follow-up, liver function assay, serum alpha-fetoprotein (AFP) levels and abdominal CT or MRI scans were performed. Patients with tumor recurrence were subjected to radiofrequency, chemotherapy, re-operation or targeted therapy as appropriate. Overall survival (OS) refers to the time between the date of...
hepatectomy and the last follow-up or death, while disease-free survival (DFS) refers to the time between the date of hepatectomy and the first recrudescence or no relapse at the last follow-up [37].

Statistical analysis
Continuous data are shown as medians (IQR 25–75) and were compared by Mann–Whitney U tests. Categorical factors are expressed as n (%) and were compared using \( \chi^2 \) tests.

The time-dependent receiver operating characteristic (t-ROC) curves was applied to confirm the discriminatory performance of inflammation-based prognostic models in assessing OS and DFS [38]. The optimal cut-off value was confirmed by X-tile analysis of the 5-year OS [39]. OS and DFS were evaluated by the Kaplan–Meier (KM) method, and discrepancies among groups were compared by the log-rank test. A Cox regression model was used for the multivariable analysis to confirm independent prognostic variables of OS and DFS. Indicators with \( p < 0.05 \) in univariate analyses were added to the multivariate Cox analysis.

RStudio (v1.4.1106), X-Tile (v3.6.1) and SPSS (v25.0) software were used for corresponding statistical analyses, and \( p < 0.05 \) was considered to be statistically significant.

Results

Patient characteristics
The clinicopathologic features of 1,502 HCC cases were shown in Table 1. The patient population had a medians age of 50 years, and 86.0% of them were male. The majority of patients (86.0%) suffered from hepatitis B virus infection, 43.3% had liver cirrhosis and 5.4% had CSPH. Most of the patients (93.3%) had good liver reserve function, and only 6.7% of the patients were Child–Pugh B grade. The medians of the prognostic indexes were 6.9 (IQR 5.5–8.9) for FAR, 2.1 (IQR 1.5–3.0) for NLR, 0.3 (IQR 0.2–0.4) for MLR, 115.7 (IQR 85.4–160.6) for PLR, and 422 (IQR 262–682) for SII. Based on the BCLC grading, 3.5% of patients were grade 0, 52.3% were grade A, 17.1% were grade B, and 27.1% were grade C. Surgical hepatectomies included 754 major and 748 minor hepatectomies.

Discriminatory performance of inflammation-based prognostic models
Upon the analysis of t-ROC curves, FAR was found to have a higher capacity to assess OS when compared with the ability of other inflammation-based prognostic models, including NLR, MLR, PLR and SII (Fig. 1a). Similarly, the area under t-ROC curve (AUC) of FAR in evaluating DFS were also greater than that of other models at every time point after liver resection (Fig. 1b). Furthermore, the prediction performance of FAR for OS and DFS was also higher than that of AFP. FAR values predicted that the AUC of 1-, 3- and 5- years OS were respectively 0.622, 0.632 and 0.640, while those of DFS were respectively 0.588, 0.641 and 0.666 (Additional File 1: Table S1).

The optimal cut-off value of inflammation-based prognostic models
We used the X-tile software to identify the optimal cut-off values of these models. As shown in Fig. 2, the values for FAR, NLR, MLR, PLR, and SII were 8.9, 3.0, 0.3, 201.5, and 876.0, respectively. Moreover, all patients were classified into low (\( \leq 8.9, n = 1126 \)) or high (\( > 8.9, n = 376 \)) FAR groups for further analysis according to this value of FAR.

Correlation between FAR and clinicopathological variables
As presented in Table 1, patients in the high FAR cohort were older, had higher serum levels (platelet, neutrophil, lymphocyte counts, etc.), lower serum albumin levels, worse liver background (higher frequency of Child–Pugh grade B, cirrhosis and CSPH), worse tumor condition (larger tumor size, multiple tumors, with macrovascular invasion (MVI) and advanced BCLC stage), and worse surgical environment (greater blood loss and transfusions, more major resections). In addition, the values of NLR, MLR, PLR and SII were also greatly up-regulated in the high FAR set (\( p < 0.05 \) for all).

Comparison of OS and DFS based on FAR
During a median follow-up of 26 months (15–38), 321 cases (28.5%) died in the low FAR group, while 179 patients (47.6%) died in the high FAR group (\( p < 0.05 \)). The 1-, 3-, and 5-year OS of the high FAR set were respectively 72.3%, 48.9%, and 36.9%, which was remarkably worse than that of the low FAR group (86.3%, 70.2%, and 61.7%, respectively; \( p < 0.05 \) for all; Fig. 3a). Furthermore, tumor recurrence occurred in 719 patients (47.8%) during follow-up, including 787 patients (43.3%) in the low FAR group and 232 patients (61.7%) in the high FAR group (\( p < 0.05 \)). Among these patients, 139 patients (23.4%) had an extrahepatic relapse, while most of the remaining patients (85.6%) had an intrahepatic recurrence. The 1-, 3-, and 5-year DFS of patients in the high FAR set were 47.4%, 20.4%, and 9.6%, respectively, which were also remarkably worse than those of the low FAR group (62.9%, 43.4%, and 33.9%, respectively; \( p < 0.05 \) for all; Fig. 3b).

Independent predictors of OS
In univariable Cox analyses, FAR, NLR, MLR, PLR and SII were significantly related to OS, as well as age, male sex, ascites, AFP, cirrhosis, tumor size, macrovascular invasion, BCLC stage, blood loss, blood transfusion and major hepatectomy. The multivariable Cox
| Variables                        | Total (n = 1502) | Low FAR (n = 1126) | High FAR (n = 376) | P value |
|----------------------------------|------------------|--------------------|--------------------|---------|
| Age(years)                       | 50 (43, 59)      | 50 (42, 59)        | 52 (45, 60)        | 0.017   |
| Sex                              |                  |                    |                    | 0.242   |
| Male                             | 1291 (86.0)      | 961 (85.3)         | 330 (87.8)         |         |
| Female                           | 211 (14.0)       | 165 (14.7)         | 46 (12.2)          |         |
| Positive HBsAg                   | 1297 (86.4)      | 979 (86.9)         | 318 (84.6)         | 0.246   |
| Positive anti-HCV                | 2.1 (1.5)        | 1.8 (1.6)          | 4 (1.1)            | 0.455   |
| Platelet count (10^9/L)          | 207 (160, 266)   | 192 (149, 243)     | 263 (211, 336)     | < 0.001 |
| Neutrophil count (10^9/L)        | 3.6 (2.8, 4.8)   | 3.3 (2.6, 4.4)     | 4.5 (3.6, 5.9)     | < 0.001 |
| Lymphocyte count (10^9/L)        | 1.7 (1.4, 2.2)   | 1.8 (1.4, 2.2)     | 1.7 (1.3, 2.1)     | < 0.001 |
| Monocyte count (10^9/L)          | 0.5 (0.4, 0.6)   | 0.4 (0.3, 0.6)     | 0.6 (0.4, 0.8)     | < 0.001 |
| Total bilirubin (μmol/L)         | 13.1 (9.7, 17.9) | 13.2 (9.9, 17.8)   | 12.8 (9.4, 18.2)   | 0.615   |
| Albumin (g/L)                    | 39.4 (36.2, 42.4)| 40.3 (37.4, 43.3)  | 35.9 (33.5, 39.2)  | < 0.001 |
| ALT (U/L)                        | 35 (24, 50)      | 35 (24, 50)        | 34 (22, 54)        | 0.813   |
| AST (U/L)                        | 39 (29, 57)      | 37 (29, 54)        | 46 (32, 69)        | < 0.001 |
| Prothrombin time (s)             | 12.8 (12.0, 13.6)| 12.7 (12.0, 13.6)  | 12.9 (12.2, 13.9)  | 0.106   |
| Fibrinogen (g/L)                 | 2.7 (2.2, 3.4)   | 2.5 (2.1, 2.9)     | 4.0 (3.5, 4.7)     | < 0.001 |
| Child–Pugh grade                 |                  |                    |                    | < 0.001 |
| A                                | 1401 (93.3)      | 1076 (95.6)        | 325 (86.4)         |         |
| B                                | 101 (6.7)        | 50 (4.4)           | 51 (13.6)          |         |
| AFP (ng/mL)                      | 4.49             |                    |                    |         |
| ≥ 400                            | 638 (42.5)       | 472 (41.9)         | 166 (44.1)         |         |
| < 400                            | 864 (57.5)       | 654 (58.1)         | 210 (55.9)         |         |
| FAR                              | 6.9 (5.5, 8.9)   | 6.2 (5.2, 7.3)     | 10.9 (9.6, 13.1)   | < 0.001 |
| NLR                              | 2.1 (1.5, 3.0)   | 1.9 (1.4, 2.5)     | 2.9 (2.0, 4.1)     | < 0.001 |
| PLR                              | 115.7 (85.4, 160.6)| 104.6 (79.5, 141.7)| 157.0 (116.3, 210.5)| < 0.001 |
| MLI                              | 0.3 (0.2, 0.4)   | 0.2 (0.2, 0.3)     | 0.3 (0.3, 0.5)     | < 0.001 |
| SII                              | 422 (262, 682)   | 354 (229, 543)     | 744 (485, 1156)    | < 0.001 |
| CSPH                             | 136 (9.1)        | 111 (9.9)          | 25 (6.6)           | 0.060   |
| Ascites                          | 169 (11.3)       | 106 (9.4)          | 63 (16.8)          | < 0.001 |
| Cirrhosis                        | 680 (45.3)       | 527 (46.8)         | 153 (40.7)         | 0.039   |
| Tumour size                      |                  |                    |                    | < 0.001 |
| > 5                              | 883 (58.8)       | 570 (50.6)         | 313 (83.2)         |         |
| ≤ 5                              | 619 (41.2)       | 556 (49.4)         | 63 (16.8)          |         |
| Tumour number                    |                  |                    |                    | 0.035   |
| Multiple                         | 288 (19.2)       | 202 (17.9)         | 86 (29.9)          |         |
| Single                           | 1214 (80.8)      | 924 (82.1)         | 290 (77.1)         |         |
| MVI                              | 393 (26.2)       | 241 (21.4)         | 152 (38.7)         | < 0.001 |
| BCLC stage                       |                  |                    |                    | < 0.001 |
| 0                                | 53 (3.5)         | 51 (4.5)           | 2 (0.5)            |         |
| A                                | 785 (52.3)       | 633 (56.2)         | 152 (40.4)         |         |
| B                                | 257 (17.1)       | 192 (17.1)         | 65 (17.3)          |         |
| C                                | 407 (27.1)       | 250 (22.2)         | 157 (41.8)         |         |
| Blood loss (mL)                  |                  |                    |                    | < 0.001 |
| ≥ 400                            | 541 (36.0)       | 366 (32.5)         | 175 (46.5)         |         |
| < 400                            | 961 (64.0)       | 760 (67.5)         | 201 (53.5)         |         |
| Blood transfusion                | 198 (13.2)       | 123 (10.9)         | 75 (19.9)          | < 0.001 |
| Extent of resection              |                  |                    |                    | < 0.001 |
| Major hepatectomy                | 754 (50.2)       | 513 (45.6)         | 241 (64.1)         |         |
| Minor hepatectomy                | 748 (49.8)       | 613 (54.4)         | 135 (35.9)         |         |
analysis revealed that FAR (HR 1.230, 95% CI 1.001–1.510; \( p = 0.048 \)) was an independent risk index of OS. Other independent prognostic factors included AFP, PLR, SII, CSPH, tumor size and blood loss (Table 2).

### Independent predictors of DFS

Univariable Cox analyses revealed that these inflammation-based prognostic models (FAR, NLR, MLR, PLR, and SII) were significantly related to DFS, as well as age, male sex, HBsAg, AFP, CSPH, ascites, tumor size, BCLC stage, blood loss and transfusion, and major hepatectomy. In the multivariable Cox analysis, FAR (HR 1.211, 95% CI 1.014–1.445; \( p = 0.035 \)) was shown as an independent predictive parameter of DFS, followed closely by HBsAg, AFP, CSPH, tumor size, BCLC stage and blood loss (Table 3).

### Subgroup analyses

Using the cut-off value of 8.9, patients with low AFP were divided into two distinct subgroups with remarkably disparate OS and DFS (\( p < 0.001 \) for all, Fig. 4a, b). Similarly, OS and DFS in the high FAR subgroup were expressively worse than those in the low FAR subgroup for patients with high AFP (\( p < 0.001 \) for all, Fig. 4c, d). Furthermore, low and high FAR were also divided according to NLR and MLR into two subgroups with meaningfully different OS and DFS (Additional File 1: Figs. S1 and S 2). As for PLR and SII, there were significant differences in each subgroup, except for DFS in the high PLR group, as well as OS and DFS in the high SII group (Additional File 1: Figs. S3 and S4).

### Discussion

In this study, we compared differences in the prognostic ability of FAR, NLR, MLR, PLR and SII in HCC patients subjected to hepatectomy. The discriminatory performance of FAR was found to be greater than that of other prognostic models. In addition, preoperative FAR was an independent prediction parameter of OS and DFS. When compared with AFP, FAR showed a higher predictive value and consistent prognostic ability for patients with disparate clinicopathological features. Therefore, FAR is a meaningful inflammation-based predictor in patients with HCC subjected to liver resection.

Currently, many researchers have suggested that SIR is closely connected with tumorigenesis and tumor development [4–6]. Interestingly, fibrinogen is not only an acute phase reactive protein that reflects SIR, but also a vital index involved in maintaining hemostasis, and the hemostasis system also plays a key effect in the occurrence and development of malignancies [40]. According to its ability to directly bind to members of the transforming growth factor-\( \beta \), vascular endothelial growth factor, fibroblast growth factor and platelet-derived
Fig. 2 X-tile analyses to determine the optimal cut-off values of a FAR, b NLR, c MLR, d PLR and e SII. The optimal cut-off values of FAR, NLR, MLR, PLR and SII were 8.9, 3.0, 0.3, 201.5, and 876.0, respectively. FAR, fibrinogen-albumin ratio; NLR, neutrophil-lymphocyte ratio; MLR, monocyte-lymphocyte ratio; PLR, platelet-lymphocyte ratio; SII, systemic immune-inflammation index; AFP, alpha-fetoprotein.
Fig. 3 Kaplan–Meier curves illustrating a OS (p < 0.001) and b DFS (p < 0.001) based on different risk groups of FAR in the entire cohort. OS overall survival; DFS disease-free survival; FAR, fibrinogen−albumin ratio

Table 2 Univariable and multivariable analyses to identify independent prognostic indicators of overall survival in patients with HCC

| Variables                        | Overall survival |                    |                  |
|----------------------------------|------------------|--------------------|------------------|
|                                  | Univariable HR (95% CI) | p value | Multivariable HR (95% CI) | p value |
| Age (years)                      | 0.988 (0.980, 0.996) | 0.003 | 0.992 (0.984,1.000) | 0.050 |
| Male sex                         | 1.442 (1.085, 1.917) | 0.012 | 1.293 (0.967, 1.729) | 0.083 |
| Positive HBsAg                    | 1.320 (0.995, 1.751) | 0.054 |                  |      |
| Positive anti-HCV                 | 0.634 (0.263, 1.531) | 0.311 |                  |      |
| Child–Pugh grade B               | 1.340 (0.962, 1.886) | 0.084 |                  |      |
| AFP ≥ 400 ng/mL                  | 1.767 (1.482,2.107) | <0.001 | 1.346 (1.120, 1.618) | 0.002 |
| FAR                              | 1.961 (1.632,2.355) | <0.001 | 1.230 (1.001, 1.510) | 0.048 |
| NLR                              | 1.936 (1.611,2.326) | <0.001 | 1.045 (0.801, 1.362) | 0.748 |
| PLR                              | 1.839 (1.466,2.307) | <0.001 | 0.739 (0.548,0.998) | 0.049 |
| MLR                              | 1.945 (1.632,2.319) | <0.001 | 1.166 (0.940,1.446) | 0.163 |
| SII                              | 2.210 (1.809,2.700) | <0.001 | 1.455 (1.053,2.010) | 0.023 |
| CSPH                             | 1.390 (1.050,1.840) | 0.021 | 1.369 (1.022,1.833) | 0.035 |
| Ascites                          | 1.471 (1.149,1.883) | 0.002 | 1.186 (0.914,1.539) | 0.198 |
| Cirrhosis                        | 1.085 (0.910,1.294) | 0.364 |                  |      |
| Tumor size ≥ 5 cm                | 2.708 (2.200,3.334) | <0.001 | 1.500 (1.180,1.907) | 0.001 |
| Multiple number                  | 1.093 (0.871,1.371) | 0.441 |                  |      |
| MVI                              | 3.484 (2.920,4.156) | <0.001 | 1.522 (0.711,3.256) | 0.279 |
| BCLC stage C                     | 8.773 (3.619,21.267) | <0.001 | 2.693 (0.833,8.686) | 0.097 |
| Blood loss ≥ 400 ml              | 2.028 (1.701,2.417) | <0.001 | 1.232 (1.011,1.501) | 0.039 |
| Blood transfusion                | 1.554 (1.225,1.971) | <0.001 | 1.083 (0.843,1.392) | 0.534 |
| Major hepatectomy                | 1.792 (1.498,2.143) | <0.001 | 1.075 (0.881,1.311) | 0.477 |

HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, alpha-fetoprotein; FAR, fibrinogen-albumin ratio; NLR, neutrophil–lymphocyte ratio; MLR, monocyte-lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune–inflammation index; CSPH, clinically significant portal hypertension; MVI, macrovascular invasion; BCLC, Barcelona Clinical Liver Cancer
growth factor, fibrinogen plays a vital role in angiogenesis, epithelial-tomesenchymal transition, proliferation, and metastasis of cancer cells [40, 41]. Moreover, studies have shown that increased plasma fibrinogen is positively correlated with low survival rate of cancer patients [42], and adjuvant therapy that down-regulates plasma fibrinogen level may effectively prolong long-term survival of cancer patients [43]. Albumin is a commonly applied indicator to evaluate a patient’s nutritional and immune status, and it can stabilize DNA replication and enhance the immune response, thereby inhibiting tumor progression [44]. In addition, reduced serum albumin is often closely related to poor outcomes in cancer patients [45]. FAR plays an mechanistically vital role in SIR, coagulation and nutrition, and is closely related to the increased metastatic potential caused by tumor cell survival, adhesiveness and intraversion [46]. These may be the critical reasons and mechanisms why FAR can be a powerful prognostic factor for cancer patients.

In this study, t-ROC analyses showed that FAR was greatly better than other inflammation prognostic models, including NLR, MLR, PLR, and SII, in estimating postoperative outcomes of patients with HCC. The optimum cut-off value of FAR was determined to be 8.9 by the X-tile analysis. High FAR (>8.9) was more possibly to happen in patients with worse cancer condition (e.g. larger tumor size, multiple tumors, accompanied by MVI and advanced BCLC staging), which suggests that FAR may reflect HCC progression and metastasis. Through a survival analysis, we found that OS and DFS were remarkably worse in patients with high FAR, as compared with patients with low FAR. In addition, univariable and multivariable analyses determined that high FAR was an independent predictive indicator for OS and DFS. Thus, these results suggest that FAR can be used as a satisfactory prognostic tool for HCC patients subjected to hepatic resection.

Other inflammation-based prognostic models were evaluated and compared to FAR, but did not show

| Variables | Disease-free survival |
|-----------|-----------------------|
|           | Univariable | Multivariable |
|           | HR (95% CI) | p value | HR (95% CI) | p value |
| Age (years) | 0.988 (0.982, 0.994) | <.001 | 0.994 (0.987, 1.001) | 0.078 |
| Male sex | 1.292 (1.033, 1.616) | 0.025 | 1.170 (0.927, 1.478) | 0.187 |
| Positive HBsAg | 1.603 (1.259, 2.041) | <.001 | 1.509 (1.167, 1.951) | 0.002 |
| Positive anti-HCV | 0.775 (0.415, 1.447) | 0.424 |             |         |
| Child–Pugh grade B | 1.167 (0.870, 1.565) | 0.302 |             |         |
| AFP ≥ 400 ng/mL | 1.560 (1.351, 1.801) | <.001 | 1.277 (1.095, 1.489) | 0.002 |
| FAR | 1.534 (1.311, 1.796) | <.001 | 1.211 (1.014, 1.445) | 0.035 |
| NLR | 1.542 (1.318, 1.803) | <.001 | 1.086 (0.866, 1.362) | 0.474 |
| PLR | 1.646 (1.350, 2.008) | <.001 | 0.970 (0.744, 1.265) | 0.821 |
| MLR | 1.453 (1.257, 1.679) | <.001 | 1.055 (0.878, 1.267) | 0.568 |
| SII | 1.676 (1.402, 2.005) | <.001 | 1.143 (0.857, 1.524) | 0.364 |
| CSPH | 1.306 (1.033, 1.652) | 0.026 | 1.319 (1.030, 1.689) | 0.028 |
| Ascites | 1.303 (1.054, 1.610) | 0.014 | 1.129 (0.903, 1.411) | 0.287 |
| Cirrhosis | 1.150 (0.996, 1.328) | 0.056 |             |         |
| Tumor size ≥ 5 cm | 2.024 (1.732, 2.364) | <.001 | 1.348 (1.121, 1.620) | 0.001 |
| Multiple number | 1.057 (0.876, 1.275) | 0.565 |             |         |
| MVI | 2.222 (1.910, 2.584) | <.001 | 0.829 (0.424, 1.622) | 0.584 |
| BCLC stage C | 4.951 (2.835, 8.646) | <.001 | 3.109 (1.303, 7.416) | 0.011 |
| Blood loss ≥ 400 ml | 1.860 (1.609, 2.149) | <.001 | 1.338 (1.136, 1.575) | <.001 |
| Blood transfusion | 1.312 (1.056, 1.629) | 0.014 | 0.951 (0.755, 1.200) | 0.674 |
| Major hepatectomy | 1.663 (1.438, 1.924) | <.001 | 1.144 (0.972, 1.346) | 0.106 |

HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, alpha-fetoprotein; FAR, fibrinogen-albumin ratio; NLR, neutrophil–lymphocyte ratio; MLR, monocyte–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune–inflammation index; CSPH, clinically significant portal hypertension; MVI, macrovascular invasion; BCLC, Barcelona Clinical Liver Cancer
independent prognostic value. Previous studies have shown that NLR can independently predict poor outcomes of HCC patients who underwent hepatectomy. However, in our research, NLR was not found to be an independent predictor, which is similar to results from the United Kingdom [47]. In parallel, Kaida et al. [12] found that preoperative PLR could predict the recurrence of HCC in patients who exceeded the Milan criteria after liver resection. Moreover, Yang et al. [48] showed that preoperative PLR was a negative survival indicator after liver resection for HBV-related HCC. We found that high PLR was also related to poor OS and DFS, even though DFS was not significant in the multivariate analysis, and there was no advantage over other models in predicting prognosis. Similar results were found for MLR and SII. The poor prognostic ability of these models in the multivariate analysis may be due to their association with FAR. In addition, other prognostic models showed weaker prognostic effects when compared with FAR. Therefore, we conclude that FAR was a better prognostic predictor in patients with HCC subjected to liver resection, when compared with existing inflammation-based prognosis models.

Recently, AFP is the most commonly applied index to evaluate the poor outcomes of HCC patients. In this research, AFP was confirmed as an independent predictive marker of OS and DFS in HCC patients subjected to liver resection. Surprisingly, t-ROC analyses showed that FAR had higher discriminatory performance than AFP in both OS and DFS. A subgroup analysis in which cases were divided according to both their FAR and AFP was performed. This analysis suggested that, compared with AFP, FAR was a better model for estimating the prognosis of HCC patients undergoing liver resection.
hepatectomy. Similar results have been obtained in other models. Considering that patients with high FAR presented poor prognosis, perioperative adjuvant therapies may assist to decrease the recurrence risk in these patients, prolong survival and improve quality of life. Moreover, closer follow-up may be considered so that recurrence can be detected earlier in these patients and then treated as soon as possible.

However, this study also have some limitations. Firstly, most patients suffered from HBV-related HCC, thus, the prognostic feasibility of FAR in patients with HCC due to other causes needs more evidence. Secondly, because our center does not detect CRP in routine blood tests before surgical operations, this study did not analyze inflammation markers related to CRP. Furthermore, this was a retrospective and single-center research, so further researches are required to ascertain our findings.

Conclusion
Preoperative FAR can more accurately predict OS and DFS than previously established inflammation-based prognostic models and AFP in patients undergoing hepatectomy for HCC. Its availability, low cost and convenience makes FAR a promising inflammation-based tool to assess the prognosis of HCC patients and may support future treatment decisions.

Abbreviations
HCC: Hepatocellular carcinoma; SIR: Systemic inflammation response; OS: Overall survival; DFS: Disease-free survival; FAR: Fibrinogen-to-albumin ratio; NLR: Neutrophil–lymphocyte ratio; MCR: Monocyte–lymphocyte ratio; CRP: C-reactive protein; PLR: Platelet–lymphocyte ratio; SII: Systemic immune–inflammation index; mGPS: Modified Glasgow outcome scale; CAR: C-reactive protein-to-albumin ratio; CRP: C-reactive protein; AFP: α-Fetoprotein; MVI: Macrovascular invasion; CSPH: Clinically significant portal hypertension; BCLC: Barcelona Clinical Liver Cancer; t-ROC: Time-dependent receiver operating characteristic.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12876-022-02328-4.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was conducted in compliance with the Helsinki Declaration and approved by the institutional Ethics Committee of Guangxi Medical University Cancer Hospital, and all patients provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 18 February 2022 Accepted: 11 May 2022
Published online: 23 May 2022

References
1. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.
2. Heinbach JK, Kulik LM, Finn RS, Sirin C, Abecasis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepato cellular carcinoma. Hepatology. 2018;67(1):358–80.
3. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;45(7203):436–44.
5. Diakos CI, Charles KA, McMllian OC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503.
6. Greten FR, Grivennikov S. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.
7. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27(3):553–61.
8. Cannon NA, Meyer J, Iyengar P, Ahr C, Westover KD, Choy H, Timmerman R. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thoracic Oncol Off J Int Assoc Study Lung Cancer. 2015;10(2):280–5.
9. Mano Y, Shiraibe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K, Aishima S, Ikegami T, Yoshizumi T, Yamanaka T, Maelaya Y. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013;258(2):301–5.
10. Cananzi F, Minerva EM, Samà L, Ruspi L, Scolfari C, Conti L, Fumagalli Romario Li, Quagliuolo VL. Preoperative monocyte-to-lymphocyte ratio predicts recurrence in gastrointestinal stromal tumors. J Surg Oncol. 2019;119(1):12–20.
11. Zhang M, Wang K, Zheng H, Zhao X, Xie S, Liu C. Monocyte lymphocyte ratio predicts the new-onset of chronic kidney disease: a cohort study. Clin Chir Acta. 2020;503:181–9.
12. Kaida T, Nitta H, Kitano Y, Yamamura K, Arima K, Higashi T, Taki K, Nakamato A, Ishiko T, Beppu T, Baba H. Preoperative platelet-to-lymphocyte ratio can predict recurrence beyond the Milan criteria after hepatectomy for patients with hepatocellular carcinoma. Hepatol Res Offl J Jpn Soc Hepatol. 2017;47(10):991–9.
13. Schobert IT, Savic LJ, Chaparro J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol. 2020;30(10):5663–73.
14. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.
15. Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–72.

16. van Dijk M, Pot GK. The effects of nutritional interventions on recurrence in survivors of colorectal adenomas and cancer: a systematic review of randomised controlled trials. Eur J Clin Nutr. 2016;70(5):566–73.

17. Mantzourou M, Routelidakis A, Theocharis S, Giaginis C. Clinical value of nutritional status in cancer: what is its impact and how it affects disease progression and prognosis? Nutr Cancer. 2017;69(8):1151–76.

18. Zhang H, Ren D, Jin X, Wu H. The prognostic value of modified Glasgow prognostic score in pancreatic cancer: a meta-analysis. Cancer Cell Int. 2020;20:462.

19. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DSJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DSJ. Prognostic value of the C-reactive protein to albumin ratio: a novel inflammation-based prognostic indicator in osteosarcoma. Oncol Targets Ther. 2017;10:5255–61.

20. Li YJ, Yao K, Lu MX, Zhang WB, Xiao C, Tu CQ. Prognostic value of the C-reactive protein to albumin ratio: a novel inflammation-based prognostic indicator in osteosarcoma. Oncol Targets Ther. 2017;10:5255–61.

21. Polterauer S, Grimm C, Seebacher V, Concin N, Martus C, Tomovski C, Husslein H, Leipold H, Helfer-Frischmuth K, Tempfer C, Reinhallter A, Helfer L. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist. 2009;14(10):979–85.

22. Ghanim B, Hoda MA, Klikovits T, Winter MP, Almohammadi A, Grusch M, Dome B, Arns M, Schenk P, Jakopovic M, Samzarova M, Bircir L, Filipi M, Laslo V, Klepetko W, Berger W, Hagedus B. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br J Cancer. 2014;110(4):984–90.

23. Gan W, Yi Y, Fu Y, Huang J, Lu Z, Jing C, Fan J, Zhou J, Qiu S. Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study. J Cancer. 2018;9(1):148–56.

24. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Helfer-Frischmuth K, Tempfer C, Reinhallter A, Helfer L. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multicentre trial. Br J Cancer. 2010;102(6):952–60.

25. Zhao J, Zhao M, Jin B, Yu F, Hu X, Yen Y, Zhang J, Luo Y, Zhang L, Zheng S, Zhou Q, Li H, Liu Y, Qiu X. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen. BMC Cancer. 2012;12(1):330.

26. Tan Z, Zhang M, Han Q, et al. A novel blood test of cancer prognosis in esophageal squamous cell carcinoma: the Fibrinogen/Albumin Ratio. J Cancer. 2017;8(6):5468–553.

27. Jones JM, McGonigle NC, McAnespie M, Caw GM, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer Int Assoc Study Lung Cancer. 2006;53(1):97–101.

28. Matsuda S, Takeuchi H, Kawaikubo H, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Onuma T, Kitagawa Y. Cumulative prognostic score based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol. 2015;22(11):302–10.

29. An Q, Liu W, Yang Y, Yang B. Preoperative fibrinogen-to-albumin ratio, a potential prognostic factor for patients with stage IIB-IV A cervical cancer. BMC Cancer. 2020;20(1):1691.

30. Zhang LP, Ren H, Du YY, Wang CF. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection. World J Gastroenterol. 2020;26(46):7382–404.

31. Wang YY, Liu ZZ, Xu D, Liu M, Wang K, Xing BC. Fibrinogen-albumin ratio index (FARI): a more promising inflammation-based prognostic marker for patients undergoing hepatectomy for colorectal liver metastases. Ann Surg Oncol. 2019;26(11):3682–92.

32. Xu Q, Yan Y, Gu S, et al. A novel inflammation-based prognostic score: the fibrinogen/albumin ratio predicts prognosis of patients after curative resection for hepatocellular carcinoma. J Immunol Res. 2018;2018:4925498.

33. Brux P, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.

34. Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatol Off J Am Assoc Study Liver Dis. 2015;61(2):526–36.

35. Pol B, Campan P, Hardwigsen J, Borti G, Pons J, Le Treut YP. Morbidity of major hepatic resections: a 100-case prospective study. Eur J Surg. 1999;165(S):446–53.

36. Mai RY, Ye JZ, Long ZR, Shi XM, Bai T, Chen J, Li LQ, Wu GB, Wu FX. Preoperative aspartate aminotransferase-to-platelet-ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma. Cancer Manag Res. 2019;11:1401–14.

37. Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, Clarke SJ. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Annals Surg. 2017;265(3):539.

38. Le Borgne F, Combeacue D, Gillaizeau F, Giral M, Chapal M, Giraudouze B, Foucher Y. Standardized and weighted time-dependent receiver operating characteristic curves to evaluate the intrinsic prognostic capacities of a marker by taking into account confounding factors. Stat Methods Med Res. 2018;27(11):3397–410.

39. Camp RL, Dolithic-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(21):7252–9.

40. Köngisbrügge Q, Pabinger I, Ay C. Risk factors for venous thrombembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res. 2014;133(Suppl 2):S39–43.

41. Staton CA, Brown NJ, Lewis CE. The role of fibrinogen and related factors in tumour angiogenesis and metastasis. Expert Opin Biol Ther. 2003;3(7):1105–20.

42. Yu X, Hu F, Yao Q, Li C, Zhang H, Xue Y. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study. BMC Cancer. 2016;16:480.

43. Perissanidis C, Psyris A, Cohen EE, et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):960–70.

44. Baltagi R, Savvidy R, Sfakianakis N, Portin I, Gogou M. Serum fibrinogen is a positive prognostic predictor of survival in colorectal carcinoma patients treated with transthoracic esophagectomy: a comparison with the Glasgow prognostic score. Ann Surg Oncol. 2015;22(11):302–10.

45. An Q, Liu W, Yang Y, Yang B. Preoperative fibrinogen-to-albumin ratio, a potential prognostic factor for patients with stage IIIB-IV A cervical cancer. BMC Cancer. 2020;20(1):1691.

46. Zhang LP, Ren H, Du YY, Wang CF. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection. World J Gastroenterol. 2020;26(46):7382–404.

47. Wang YY, Liu ZZ, Xu D, Liu M, Wang K, Xing BC. Fibrinogen-albumin ratio index (FARI): a more promising inflammation-based prognostic marker for patients undergoing hepatectomy for colorectal liver metastases. Ann Surg Oncol. 2019;26(11):3682–92.

48. Xu Q, Yan Y, Gu S, et al. A novel inflammation-based prognostic score: the fibrinogen/albumin ratio predicts prognosis of patients after curative resection for hepatocellular carcinoma. J Immunol Res. 2018;2018:4925498.

49. Brux J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.